Altitude-AD Alzheimer’s Study

Advancing Health and Medicine Through Clinical Research Trials

With our latest clinical trials and comprehensive medical research, we aim to help people experiencing mild cognitive impairment or early-stage symptoms of Alzheimer’s Disease from progressing.

  • Hidden

What Is the Altitude-AD Study?

Cognitive functions will be monitored periodically by a researcher. Altitude-AD is a phase 2/3 trial that examines how safe and effective the investigational medication ACU-193 is for people with mild cognitive impairment or early Alzheimer’s Disease.  Additionally, they will take blood samples, perform cognitive testing and imaging, including MRIs and PET scans to follow the progress.

smiling old man with a lady beside apollo study center 1

Learn more about the Altitude-AD study and the investigational medicine for infusion designed to slow the progression of mild cognitive impairment and Alzheimer’s Disease.

Alzheimer’s Disease is a progressive condition that weakens memory and other mental abilities. During the early stages of Alzheimer’s disease, common changes include frequent forgetfulness, difficulty with language, and trouble making plans or organizing. No cure exists, but current medications may temporarily help with your symptoms.

Eligible participants will receive the study drug for 80 weeks and close care and monitoring by an Alzheimer’s disease specialist at no cost. Reimbursement is available for study-related time and travel expenses.

Join Our Altitude-AD Alzheimer’s Study!

Are you or a loved one experiencing memory loss that makes daily duties become more challenging to perform? 

At Bradenton Research Center, we are attempting to delay the progression of Alzheimer’s disease through the Altitude-AD study. If you are dealing with memory loss and find routine chores more tedious, this study may be right for you. 

Participating in studies is voluntary, and all medical attention, care, and treatment are provided without additional cost. Contact us today.

diagnostic lab hand with glove holding tools bradenton research center

Altitude-AD Alzheimer’s Study

The primary Objective of this study is to evaluate the efficacy of AU193 infusions administered once every 4 weeks in slowing cognitive and functional decline compared to placebo based on changes from Baseline to Week 80 based on the Integrated Alzheimer’s Disease Rating Scale score. By taking part in this study, you can help find the treatment that will slow Alzheimer’s progression. The research medication or placebo will be given to eligible participants for an 18-month period, along with supervision, continued ratings, bloodwork, and imaging.

Advantages of Participating in Acumen-AD Alzheimer’s Study

Detection of early Alzheimer’s is tough, and you might not experience symptoms before learning you have it. The disease has a number of early warning signs and symptoms, such as forgetting anniversaries,  birthdays, or having trouble with a shopping list. Its causes are still not entirely known, but aging, family history, dementia, and other cardiovascular illnesses are common risk factors strongly associated with Alzheimer’s Disease.

80 week access to a research medicine

An Alzheimer's disease expert will provide close attention and supervision

Opportunity to advance Alzheimer's disease treatment

Reimbursement for travel and time spent on research activities

Participate in a study today!

As part of the Acumen-AD study, an investigational medicine is being tested to see if it can recede or slow Alzheimer’s disease from progressing. Current investigational drugs and medications help further study Alzheimer’s Disease, which impairs memory and other cognitive abilities. 

 You might be eligible for the Acumen-AD study if you show signs of Alzheimer’s Disease in its early stages. Contact us today.

Address

3924 9th Ave W, Bradenton, FL 34205

Call Us

(941) 708-0005

Email Us

info@bradentonresearch.com